ROCKVILLE, Md., Aug. 7,
2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT:
SYN), a biotechnology company developing novel anti-infective
biologic and drug candidates targeting specific pathogens that
cause serious infections and diseases, announced today
that it intends to release its financial results for the three and
six months ended June 30, 2014 on
Thursday, August 14, 2014. The
Company will hold an investor conference call on Thursday, August 14, at 8:30 am EDT.
During the call, Jeffrey Riley,
Synthetic Biologics' Chief Executive Officer, will provide an
update and review upcoming clinical milestones for the Company's
anti-infective drug pipeline to address serious infections and
diseases, including the prevention of C. difficile
infections, reducing the impact of methane producing organisms on
constipation-predominant irritable bowel syndrome (C-IBS), and the
treatment of Pertussis.
Mr. Riley will also provide a reminder that Rhonda Voskuhl, M.D., the lead investigator of
the Phase II clinical trial evaluating Trimesta™, the Company's
oral product candidate for the treatment of relapsing-remitting
multiple sclerosis (MS), is scheduled to present additional
clinical outcome data, including more detailed results on cognitive
and disability measures. Dr. Voskuhl is scheduled to present at the
2014 Joint Americas and European Committees for Treatment and
Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) on
September 12th in
Boston. In addition, C. Evan Ballantyne, Synthetic Biologics' Chief
Financial Officer, will review the Company's financial results for
the three and six months ended June 30,
2014.
Interested parties should call 1-877-870-4263 (U.S. toll free),
1-855-669-9657 (Canada toll free),
or +1 412-317-0790 (International), fifteen minutes before the
start of the call to register. Registered callers on the toll free
line may ask to be placed in the queue for the Question &
Answer Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=100224. If you are unable
to participate during the live conference call, the webcast will be
available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=100224, for 30 days after
the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.